RANCHO CORDOVA, Calif.,
Sept. 25, 2019 /PRNewswire/ -- Cesca
Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell
processing and autologous cell therapies for regenerative medicine,
and ThermoGenesis, its wholly owned device subsidiary (the
"Company"), today reported Validations of System Performance for
their X-Series® products from two prestigious academic medical
centers: Marcus Center for Cellular Cures at Duke University School of
Medicine and Lineberger Comprehensive Cancer
Center at the University of North
Carolina.
X-Wash® System: An article, entitled, "Source
Cell Preparation for the Manufacture of DUOC-01 Using a Closed
System Cell-Processing Device," was published in
the August 2019 issue of Stem
Cells Translational Medicine. DUOC-01 is a cell product derived
from cord blood CD14 monocytes, currently being studied in a
clinical trial in pediatric patients with inherited
leukodystrophies. Since the clinical benefit of the DUOC-01
population of cells is improved when the contaminating red cells
and DMSO cryoprotectant are depleted from the thawed cord blood
unit, principal author, Dr. Joanne
Kurtzberg, and her co-authors at the Duke University School of Medicine, tested whether
the semi-automated, "closed-system" X-WASH could accomplish this
precision purification typically pursued with labor intensive
"open-system" manual processes requiring the use of density
gradients and performed under a sterile hood. A total of 33
thawed units of cord blood were prepared for the manufacture of a
DUOC-01 cell population and the authors concluded: "The
X-WASH device allows for washing of thawed cord blood in a closed
system without adding density gradient solutions and proved to be
reliable and consistent across varying CBU volumes for RBC removal
and TNC recovery as needed for the manufacture of DUOC-01."
CAR-TXpress™ System: The ISCT NA Top Scoring Technologist
Abstract Award Recipient, "Validation of ThermoGenesis
CAR-TXpress™ System for Activation in Scale-up CAR T cell
Production," authored by Todd
Maguire, Paul Eldridge,
Barbara Salvodo and Kathryn McKay of
the Lineburger Advanced Cellular Therapeutics Facility, was
presented at the ISCT North America regional conference on
September 13, 2019. The authors
reported on the use of all three semi-automated
devices, X-LAB® to harvest MNCs from blood,
X-WASH to wash DMSO, growth factors, cell debris, free
viruses, etc. from cells and X-BACS™ to select, harvest
and activate T-cells with buoyant microbubbles. The authors
concluded: "The results of three experimental runs
described indicate that T lymphocytes prepared with the CAR-TXpress
System are comparable to a previous validated manual method. The
advantages of scale, reduction in the number of operator steps and
closed system processes are attractive features of the system.
Additional validation work will be needed to qualify the system,
but it has useful potential and is amenable to function across a
spectrum of scale for early to later phase production
efforts."
About Cesca Therapeutics and ThermoGenesis
Cesca Therapeutics
develops, commercializes and markets a range of automated
technologies for CAR-T and other cell-based therapies. Its device
division, ThermoGenesis, develops, commercializes and markets a
full suite of solutions for automated clinical biobanking,
point-of-care applications, and automation for immuno-oncology. The
Company has developed a semi-automated, functionally closed
CAR-TXpress™ platform to streamline the manufacturing process for
the emerging CAR-T immunotherapy market. For more information about
Cesca and ThermoGenesis, please visit:
www.cescatherapeutics.com.
Forward-Looking Statement
The statements contained
herein may include statements of future expectations and other
forward-looking statements that are based on management's current
views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics' annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/thermogenesis-reports-performance-evaluations-of-x-series-cell-processing-devices-300925271.html
SOURCE Cesca Therapeutics Inc.